Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Exosomes, as the main group of extracellular vesicles, are biologically active lipid-bilayer vesicles that are naturally released from different types of normal or tumor cells. These vesicles play an important role in intercellular communication and influence the extracellular environment and the im...
Guardado en:
Autores principales: | Min Yu, Sheng Chen, Zi Yin, Tingting Ma, Chuanzhao Zhang, Shanzhou Huang, Mohammad Reza Karimzadeh, Amir Abaas Momtazi-Borojeni |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7cc2dc4dcc8d40598ab784c274122ca0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2021) -
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017) -
Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
por: Olga V. Kovaleva, et al.
Publicado: (2021) -
Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao M, et al.
Publicado: (2015) -
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
por: Clemens Hinterleitner, et al.
Publicado: (2021)